Tag Archives: InterAx

Novo’s Wegovy Pill Off to Quick Start; New Ph3b Retatrutide Study; Lilly Launches Obesity Campaign; Biomed Initiates Two Ph3 Quadruple Agonist Trials; Alveus Advances Obesity Asset; Afrezza Label Update; January CHMP Agenda

A series of cardiometabolic-related news items has been observed from Novo Nordisk, Lilly, Biomed Industries, Alveus Therapeutics, MannKind, and EMA. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Already a member? Log in here

Early Wegovy Pill Prescription Trends; InterAx and Alveus Drug Discovery Partnership

Two cardiometabolic-related news items have been observed: Novo Nordisk tracks over 3,000 US prescriptions of Wegovy pill in the first four days of launch (view article); and InterAx and Alveus Therapeutics enter into a partnership for cardiometabolic drug discovery (view press release). Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Already a member? Log in here